Revascularisation for Ischaemic Ventricular Dysfunction

A multicentre prospective randomised open controlled trial.

Aim: To evaluate the efficacy and safety of percutaneous coronary intervention compared to optimal medical therapy alone for ischaemic left ventricular dysfunction.

Primary Endpoint: All-cause death or hospitalisation due to heart failure

Secondary Endpoints:

  • Left Ventricular Ejection Fraction (LVEF) on echocardiography at 6 months and 1 year
  • Quality of life score:
    • Kansas City Cardiomyopathy Questionnaire (KCCQ) up to 2 years
    • EuroQol EQ-5D-5L at 6 months and then yearly to the end of follow-up
  • New York Heart Association Functional (NYHA) Functional Class up to 2 years
  • Cardiovascular death over the entire duration of follow-up
  • All-cause death over the entire duration of follow-up
  • Hospitalisation for heart failure over the entire duration of follow-up
  • Acute myocardial infarction (MI) over the entire duration of follow-up
  • Appropriate implantable cardioverter defibrillator (ICD) therapy up to 2 years
  • Unplanned further revascularisation over the entire duration of follow-up
  • Canadian Cardiovascular Society (CCS) class up to 2 years
  • NHS resource use
  • Brain natriuretic peptide (BNP or NT-Pro BNP) level up to 2 years
  • Major bleeding up to 2 years

Comments are closed.